Davis Discusses Possible Implications of Public Allegations of Misconduct Against Board Directors
18 June 2018
Agenda
Partner Gardner Davis was quoted in an article in Agenda, “Allegations Can Put Board Seats on the Line,” about the potential impact that public litigation may have on a board director’s reputation and ability to carry out his or her responsibilities.
Davis said there is an important distinction when claims are made against directors in the course of litigation. “From the director’s perspective, the critical issue is whether they made a mistake of business judgment, as opposed to an allegation which goes to the director’s integrity, such as self-dealing or putting the director’s interests ahead of the shareholders’ interests,” he said.
(Subscription required.)
Davis said there is an important distinction when claims are made against directors in the course of litigation. “From the director’s perspective, the critical issue is whether they made a mistake of business judgment, as opposed to an allegation which goes to the director’s integrity, such as self-dealing or putting the director’s interests ahead of the shareholders’ interests,” he said.
(Subscription required.)
People
Related News
14 February 2025
In the News
Brian Wheeler Joins Podcast to Discuss Legal Journey
Foley & Lardner LLP partner Brian Wheeler joined the Hsu Untied podcast to discuss his legal career.
14 February 2025
In the News
Pavan Agarwal Featured in Leadership Q&A – 'Reflecting our firm’s core values drives me to do my best'
Foley & Lardner LLP partner Pavan Agarwal is featured by Law.com for his career journey, legal practice, and leadership in the article, “How I Made Practice Group Chair: ‘Keep Listening and Keep Learning,’ Says Pavan Agarwal of Foley & Lardner.”
14 February 2025
In the News
Judith Waltz on Trump Administration Deregulation Order, Impact on CMS
Foley & Lardner LLP partner Judith Waltz commented on the Trump administration's executive order requiring federal agencies cut ten regulations for each newly created one in the Modern Healthcare article, "CMS may evade Trump's sweeping deregulation order."